Will the FDA ever fast-track psychedelic drugs? 5 Questions with drug regulation expert Daniel Eisenkraft Klein
Eisenkraft Klein discusses the FDA’s new accelerated drug review program.
External link. We are not responsible for the content.
Read more ↗More From The Microdose (Berkeley)
Can an LLM get high? 5 Questions with clinical neuroscientist Ziv Ben-Zion
Ben-Zion discusses how artificial intelligence mimics the psychedelic experience.
Scientists test if ketamine has antidepressant effects under anesthesia; France is the first to approve IV ketamine for severe suicidal crisis
Plus: New research on the role of trip sitters; Various state bills move to expand psychedelics research and access
Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates
Yates discusses experimental attempts to end a psychedelic trip early.
Latest News
Learning to Die Well: Inside a Psychedelic End‑of‑Life Retreat
What if learning how to die well is also how we learn to live? Inside a psychedelic end‑of‑life retreat rooted in the...
Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy
Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore ...
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
April 22, 2026 — Forty years ago, Rick Doblin, Ph.D., incorporated the Multidisciplinary Association for Psychedelic ...
Why Ketamine Is Changing Psychiatry
Scott Shannon, MD argues that ketamine is doing more than relieving depression. It may be helping psychiatry move bey...
The Dark Side of Psychedelic Healing, According to Erica Rex (1)
A conversation on trauma, power, and the risks of trusting systems meant to heal [...] Read More... The post The Dark...
The Difficulty of Sincerity After Psychedelics
Psychedelic experiences often heighten one’s sense of authenticity and sincerity, but this can make ordinary social i...